Mar 12, 2019 / 12:30PM GMT
Gregory Allen Harrison - Barclays Bank PLC, Research Division - Research Analyst
Okay. Today we're lucky enough to have Prothena with us. We have Gene Kinney, CEO; and Tran Nguyen, CFO. My name is Greg Harrison. I'm an associate on Geoff Meacham's team, and with me is Scott Puckhaber.
Questions and Answers:
Gregory Allen Harrison - Barclays Bank PLC, Research Division - Research AnalystSo I guess we'll just get right into it, maybe start off with the prasinezumab program in Parkinson's. So you recently published the Phase 1b data. Just curious, we saw a good PK/PD profile. What, beyond that, did you guys find especially meaningful as you progressed this program?
Gene G. Kinney - Prothena Corporation plc - President, CEO & Director
Yes, I know. Well, first, Greg and Scott, thank you for having us. We very much appreciate being here. Yes, just to speak a little bit about prasinezumab. Maybe I can kind of introduce a little bit of science behind it, then we can talk about this Phase 1b results. So that's a
Trustpilot
